Research Interests: Immunology, Oncology, Translational Research, Genetic Engineering, Immunoassays/Immune Monitoring, First-in-human clinical trials

Research Interests: Immunology, Oncology, Translational Research, Genetic Engineering, Immunoassays/Immune Monitoring, First-in-human clinical trials

Education and Professional Standing

MD, University of Western Ontario, 1990
FRCPC Internal Medicine, 1994
FRCPC Hematology, 1995
MSc Health Research Methodology, 1998
Fellow of the Royal Society of Canada (FRSC), 2017

Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter’s annual publication of The World’s Most Influential Scientific Minds).

[View Dr. Crowther’s citations on PubMed]

Research Interests: Exploring ways of improving the way that we use our current anticoagulant drugs, including exploring established and novel interventions to mitigate bleeding and anticoagulant drugs in high-risk patient populations; Developing systematic reviews of key questions in hematology and thrombosis and basing guidelines on those reviews.

Education and Professional Standing

MD, University of Western Ontario, 1990
FRCPC Internal Medicine, 1994
FRCPC Hematology, 1995
MSc Health Research Methodology, 1998
Fellow of the Royal Society of Canada (FRSC), 2017

Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter’s annual publication of The World’s Most Influential Scientific Minds).

[View Dr. Crowther’s citations on PubMed]

Research Interests: Exploring ways of improving the way that we use our current anticoagulant drugs, including exploring established and novel interventions to mitigate bleeding and anticoagulant drugs in high-risk patient populations; Developing systematic reviews of key questions in hematology and thrombosis and basing guidelines on those reviews.

Dr John Eikelboom is an associate professor in the Department of Medicine at McMaster University in Hamilton, Ontario . After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University . He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.

Research Interests: Mechanisms and genetic determinants of antiplatelet drug resistance and improving its diagnosis and treatment.

Dr John Eikelboom is an associate professor in the Department of Medicine at McMaster University in Hamilton, Ontario . After earning his MBBS degree at the University of Western Australia Medical School, Australia, he completed training in Internal Medicine and Haematology at Royal Perth Hospital, Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University . He holds a Canada Research Chair in Cardiovascular Medicine from the Canadian Institutes for Health Research. Dr. Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.

Research Interests: Mechanisms and genetic determinants of antiplatelet drug resistance and improving its diagnosis and treatment.

The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:

• identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
• providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
• identifying candidate papers for triggering BMJ Wiki recs;
• feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.

HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.

HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.

The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.

Teaching

Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)

Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies

Other scholarly activities

Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.

He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.

Full publication list: click here

Research Interests: knowledge translation research; medical informatics

The Health Information Research Unit (HiRU), founded by Brian Haynes, is a knowledge refinery, whose main activity is maintaining the McMaster Premium LiteratUre Service (McMaster PLUS), a second-order peer review database of methodologically sound, clinically relevant and newsworthy peer reviewed publications. McPLUS is used for many purposes, including:

• identifying candidate papers for abstraction (American College of Physicians Journal Club, a monthly feature in the of Annals of Internal Medicine);
• providing discipline specific news feeds via the DynaMed sponsored Evidence Alerts service, or the ACP sponsored JournalWise evidence feed;
• identifying candidate papers for triggering BMJ Wiki recs;
• feeding evidence into a suite of discipline specific products like Clot+, Pain+, Prevention+, the Optimal Aging Portal and, more recently, COVID-19+ EvidenceAlerts.

HiRU has created the Clinical Query filters available on the PubMed search engine and, more recently, developed a machine learning based, highly specific algorithm to retrieve sound and clinically relevant literature.

HiRU is open to potential collaborations with any academic, not-for-profit or commercial organization whose aim is to disseminate high quality evidence. For further details on HiRU’s knowledge translation research program, click here.

The clinical research program is centered on the application of information technology to optimize the clinical management of rare bleeding disorders. The McMaster Hemophilia Research Program, based and partly supported by the Michael G. DeGroote School of Medicine, runs a worldwide epidemiology and pharmacoepidemiology research program based on the following infrastructure: a) the Canadian Bleeding Disorder Registry (CBDR), supporting clinical activities of all bleeding disorder centers in Canada and feeding a central anonymized data repository; b) the Web-available Population Pharmacokinetic Service (WAPPS) and research network, the gold standard for personalized treatment for hemophilia, covering over 550 centers worldwide, producing PopPK estimates at the point of care for all available factor concentrates; c) the Patient Reported Outcome, Burden and Experiences (PROBE), a multilingual assessment tool and research network aiming to generate robust comparative effectiveness data. For further details, click here.

Teaching

Course Coordinator and Lecturer, Health Research Methodology Course #777 (Diagnosis and Prognosis)

Lecturer, Health Research Methodology Course #721 (Introduction to Health Research Methodology) Teaching Unit: Prognostic studies

Other scholarly activities

Dr. Iorio is an Associate Editor of the Cystic Fibrosis and Genetic Disorders Review Group of Cochrane, and a member of Cochrane’s Prognosis Method Group.

He is past Chair of the Data and Demographics Committee of the World Federation of Haemophilia (WFH), Co-Chair of the World Bleeding Disorder Registry (WFH), a member of the GRADE Working Group, and a member of the COVID-END initiative.

Full publication list: click here

Research Interests: knowledge translation research; medical informatics

Research Interests: Host-virus interactions and viral therapeutics for cancer

Research Interests: Host-virus interactions and viral therapeutics for cancer

Research Interests: Manufacturing of adenoviral vectors for pre-clinical and clinical applications

Research Interests: Manufacturing of adenoviral vectors for pre-clinical and clinical applications

Research interests are in the specific interactions between antibodies and their target antigens on platelets, leading to thrombocytopenia and/or thrombosis. Heparin induced thrombocytopenia and Immune thrombocytopenia (ITP) are great models for identifying key factors involved in the pathogenesis of the immune responses leading to low platelet counts. Our research focuses on the cellular and humoral immunity and the downstream effects on platelet physiology. We use our research to identify the pathology from patient samples and create in-vitro models that could explain our findings and further our understanding of the issues at hand.

Research interests are in the specific interactions between antibodies and their target antigens on platelets, leading to thrombocytopenia and/or thrombosis. Heparin induced thrombocytopenia and Immune thrombocytopenia (ITP) are great models for identifying key factors involved in the pathogenesis of the immune responses leading to low platelet counts. Our research focuses on the cellular and humoral immunity and the downstream effects on platelet physiology. We use our research to identify the pathology from patient samples and create in-vitro models that could explain our findings and further our understanding of the issues at hand.

Research Interests: Chemical Immunomodulatory approaches to combat cancer, multivalent metastatic cell targeting oligomers, covalent re-engineering of immunological machinery and the cancer cell surface

Research Interests: Chemical Immunomodulatory approaches to combat cancer, multivalent metastatic cell targeting oligomers, covalent re-engineering of immunological machinery and the cancer cell surface

Research Interests: Epidemiology of arterial and venous thrombotic diseases with a specific focus on utilization of evidence-based therapies.

Research Interests: Epidemiology of arterial and venous thrombotic diseases with a specific focus on utilization of evidence-based therapies.

Research Interests: Tumor immunity, cancer vaccines, adoptive T cell therapy, oncolytic viruses

Research Interests: Tumor immunity, cancer vaccines, adoptive T cell therapy, oncolytic viruses

Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.

By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.

Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.

Dr. Weitz is Professor of Medicine and Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute. Board Certified in Internal Medicine, Hematology and Medical Oncology, Dr. Weitz focuses his clinical practice on patients with thrombotic disorders. His research spans the spectrum from basic studies in the biochemistry of blood coagulation and fibrinolysis to animal models of thrombosis and on to clinical trials of antithrombotic therapy. The breadth of his work is highlighted by his over 500 publications in journals as diverse as the Journal of Clinical Investigation, Journal of Biological Chemistry, Biochemistry, Circulation, Blood, Annals of Internal Medicine, New England Journal of Medicine and Lancet, and 60 book chapters. The recipient of numerous awards, Dr. Weitz is a Fellow of the American Heart Association, the Royal Society of Canada and the Canadian Academy of Health Sciences.

By focusing on the basic mechanisms by which anticoagulants (blood thinners) and thrombolytic agents (clot digesting drugs) work, Dr. Weitz has opened new avenues of investigation. His demonstration that thrombin bound to fibrin is resistant to inactivation by available anticoagulants stimulated the development of new drugs, some of which are already being used in clinical practice. Through other research, Dr. Weitz has provided an explanation for the puzzling clinical observation that the clot digesting drug, tissue-type plasminogen activator or t-PA, produces more bleeding than was originally anticipated. This work has paved the way for new drugs that may be safer than t-PA.

Dr. Weitz is involved in clinical trials examining optimal methods for prevention, diagnosis and treatment of clotting disorders. He also is an active participant in the education of medical students, residents, and postdoctoral fellows. In addition, he coordinates a graduate course in medical sciences and his laboratory is a fertile training ground for graduate students and postdoctoral fellows in medical sciences and bioengineering.

Our research is concentrated upon understanding why people with diabetes mellitus are predisposed to cardiovascular disease.

The last few decades have witnessed a dramatic, worldwide increase in the prevalence of diabetes mellitus. Complications associated with diabetes make it a leading cause of blindness, renal failure and lower limb amputations in adults as well as an important, independent risk factor for atherosclerotic cardiovascular disease (CVD). In fact, CVD accounts for over 65% of diabetic mortality. The treatment and prevention of diabetic complications such as CVD is currently limited by our lack of understanding of the mechanisms by which diabetes promotes atherosclerosis – the underlying cause of CVD.

Our research is concentrated upon understanding why people with diabetes mellitus are predisposed to cardiovascular disease.

The last few decades have witnessed a dramatic, worldwide increase in the prevalence of diabetes mellitus. Complications associated with diabetes make it a leading cause of blindness, renal failure and lower limb amputations in adults as well as an important, independent risk factor for atherosclerotic cardiovascular disease (CVD). In fact, CVD accounts for over 65% of diabetic mortality. The treatment and prevention of diabetic complications such as CVD is currently limited by our lack of understanding of the mechanisms by which diabetes promotes atherosclerosis – the underlying cause of CVD.